سعر ستروكا 75مجم 30 قرص 2022

Stroka 75 mg (Multi-Apex, Egypt): clopidogrel 75 mg film-coated tablets, a P2Y12 ADP-receptor antiplatelet agent; pack of 30 tablets.

• Non-ST-elevation acute coronary syndrome (with aspirin) and STEMI, to reduce MI and strokePopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Recent MI, recent stroke or established peripheral arterial disease, to reduce MI and strokePopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Bleeding is the main clinically important adverse reaction (including major and life-threatening bleeding, epistaxis, hematuria, bruising); postmarketing reports include agranulocytosis and other blood disorders and hypersensitivity reactions.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Active pathological bleeding such as peptic ulcer or intracranial hemorrhage.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity (e.g. anaphylaxis) to clopidogrel or any component of the product.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: diminished antiplatelet effect in CYP2C19 poor metabolizers (two loss-of-function alleles); consider another P2Y12 inhibitor in identified poor metabolizers.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Increases the risk of bleeding; if possible interrupt for 5 days before surgery with major bleeding risk and restart as soon as hemostasis is achieved; premature discontinuation increases cardiovascular risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Thrombotic thrombocytopenic purpura (TTP), sometimes fatal, has been reported, sometimes after short exposure; requires urgent treatment including plasma exchange.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Omeprazole or esomeprazole (CYP2C19 inhibitors)Reduce active-metabolite levels and platelet inhibition; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
• Strong CYP2C19 inducers (e.g. rifampin)Increase active metabolite and bleeding risk; avoid.DailyMed (U.S. National Library of Medicine)
• NSAIDs, warfarin, SSRIs/SNRIsIncreased risk of bleeding.DailyMed (U.S. National Library of Medicine)

• Published case reports and postmarketing data have not identified drug-associated risks of major birth defects or miscarriage; therapy for MI or stroke should not be withheld because of fetal concerns.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; present in rat milk; no adverse effects observed in a small number of postmarketing cases; weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Clopidogrel: Prodrug whose active metabolite irreversibly binds the platelet P2Y12 ADP receptor, inhibiting platelet activation and aggregation.